Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks. The secondary objectives of the study are as follows: * To determine the effect of HD vs. aflibercept on anatomic and other visual measures of response * To evaluate the safety, immunogenicity, and pharmacokinetics (PK) of aflibercept
Epistemonikos ID: 700dd8462f454514e70c0f6859321684a54731ef
First added on: May 07, 2024